Advertisement
CHRS vs DERM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and DERM is a Hold.
CHRS's RSI Indicator recovers from oversold territory
The RSI Indicator for CHRS moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 33 of the 35 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 70 cases where CHRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 188 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 79 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
CHRS moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.895) is normal, around the industry mean (26.782). P/E Ratio (3.236) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DERM in downward trend: 10-day moving average moved below 50-day moving average on September 28, 2026
The 10-day moving average for DERM crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DERM as a result. In 79 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for DERM turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
DERM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DERM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for DERM entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DERM's RSI Indicator exited the oversold zone, 26 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where DERM advanced for three days, in 231 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
DERM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.650) is normal, around the industry mean (43.873). P/E Ratio (39.077) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.865) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. DERM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DERM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
CHRS | DERM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 96 | |
PRICE GROWTH RATING 1..100 | 86 | 63 | |
P/E GROWTH RATING 1..100 | 68 | 33 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CHRS's Valuation (53) in the Biotechnology industry is in the same range as DERM (58). This means that CHRS’s stock grew similarly to DERM’s over the last 12 months.
CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DERM (100). This means that CHRS’s stock grew similarly to DERM’s over the last 12 months.
DERM's SMR Rating (96) in the Biotechnology industry is in the same range as CHRS (99). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.
DERM's Price Growth Rating (63) in the Biotechnology industry is in the same range as CHRS (86). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.
DERM's P/E Growth Rating (33) in the Biotechnology industry is somewhat better than the same rating for CHRS (68). This means that DERM’s stock grew somewhat faster than CHRS’s over the last 12 months.
| CHRS | DERM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 88% | 3 days ago 81% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Advances ODDS (%) | 15 days ago 77% | 15 days ago 86% |
| Declines ODDS (%) | 8 days ago 90% | 1 day ago 84% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CHRS’s FA Score shows that 0 FA rating(s) are green while DERM’s FA Score has 1 green FA rating(s).
- CHRS’s FA Score: 0 green, 5 red.
- DERM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CHRS’s TA Score shows that 4 TA indicator(s) are bullish while DERM’s TA Score has 4 bullish TA indicator(s).
- CHRS’s TA Score: 4 bullish, 5 bearish.
- DERM’s TA Score: 4 bullish, 6 bearish.
Price Growth
CHRS (@Biotechnology) experienced а +3.88% price change this week, while DERM (@Pharmaceuticals: Generic) price change was -7.79% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -14.96%, and the average quarterly price growth was -16.57%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.86%. For the same industry, the average monthly price growth was -3.86%, and the average quarterly price growth was +15.65%.
Reported Earning Dates
CHRS is expected to report earnings on Nov 09, 2026.
DERM is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-6.67% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-3.86% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SIXJ | 37.76 | 0.04 | +0.12% |
| AllianzIM U.S. Equity 6 Month Buffer10 Jan/Jul ETF (SIXJ) | |||
| ULST | 40.19 | 0.01 | +0.01% |
| State Street Ultra Short Term Bond ETF (ULST) | |||
| FEMV | 26.75 | N/A | N/A |
| Fidelity Enhanced Mid Cap Value ETF (FEMV) | |||
| IWX | 112.26 | -0.23 | -0.20% |
| iShares Russell Top 200 Value ETF (IWX) | |||
| NSI | 37.91 | -0.18 | -0.47% |
| National Security Emerging Markets Index ETF (NSI) | |||
CHRS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ARRY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ARRY could also see price increases.
| Ticker / NAME | Correlation To CHRS | 1D Price Change % | ||
|---|---|---|---|---|
| CHRS | 100% | +3.88% | ||
| ARRY - CHRS | 39% Loosely correlated | -0.83% | ||
| AXON - CHRS | 38% Loosely correlated | -0.26% | ||
| LCTX - CHRS | 36% Loosely correlated | -4.80% | ||
| AMRN - CHRS | 35% Loosely correlated | +0.43% | ||
| VIR - CHRS | 33% Poorly correlated | -6.11% | ||
More | ||||
DERM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DERM has been loosely correlated with APUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DERM jumps, then APUS could also see price increases.
| Ticker / NAME | Correlation To DERM | 1D Price Change % | ||
|---|---|---|---|---|
| DERM | 100% | -3.89% | ||
| APUS - DERM | 49% Loosely correlated | -11.15% | ||
| CHRS - DERM | 27% Poorly correlated | +3.88% | ||
| CRDL - DERM | 23% Poorly correlated | +1.69% | ||
| AMLX - DERM | 23% Poorly correlated | -2.29% | ||
| ETON - DERM | 23% Poorly correlated | -3.48% | ||
More | ||||